비오피오이드 통증 치료 시장 규모, 점유율, 성장 분석 : 약물 종류별, 통증 종류별, 투여 경로별, 최종사용자별, 지역별 - 업계 예측(2026-2033년)

Global Non-Opioid Pain Treatment Market size was valued at USD 28.52 Billion in 2024 and is poised to grow from USD 30.55 Billion in 2025 to USD 52.85 Billion by 2033, growing at a CAGR of 7.12% during the forecast period (2026-2033).

The global non-opioid pain treatment market is experiencing significant growth driven by the urgent need to mitigate opioid-related harms while effectively managing chronic pain. This market encompasses a variety of pharmaceutical products, including NSAIDs, antidepressants, anticonvulsants, and topical agents, alongside device therapies such as neuromodulation and radiofrequency ablation. The importance of this market lies in its potential to provide safer and more effective pain management solutions that reduce morbidity, minimize addiction risks, and alleviate healthcare costs. As pharmaceutical companies focus on developing targeted agents and novel formulations, device manufacturers are expanding neuromodulation technology for chronic pain relief. Additionally, payers are creating reimbursement pathways that promote the integration of these treatments into clinical practice, highlighting substantial commercial and clinical opportunities.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Non-Opioid Pain Treatment market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Non-Opioid Pain Treatment Market Segments Analysis

Global non-opioid pain treatment market is segmented by drug class, pain type, route, end-user and region. Based on drug class, the market is segmented into NSAIDs, COX-2 Inhibitors, Anticonvulsants (Gabapentinoids), SNRIs and Nerve Blocks. Based on pain type, the market is segmented into Neuropathic Pain, Musculoskeletal Pain, Post-Surgical Pain and Chronic Pain. Based on route, the market is segmented into Oral, Injectable and Topical. Based on end-user, the market is segmented into Hospitals, Pain Clinics and Retail Pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Non-Opioid Pain Treatment Market

The increasing preference among patients for non-opioid methods of pain management is prompting healthcare providers and payer organizations to incorporate these therapies into their care protocols. This growing acceptance of alternative pain management options is likely to drive pharmaceutical and medical device manufacturers to enhance their research investments, develop diverse product portfolios, and seek regulatory approval for cutting-edge non-opioid solutions. As alternative pain management methods gain clinical traction, the resulting uplift in market volume will boost payer support and enhance visibility for manufacturers. This dynamic will accelerate commercialization efforts and foster continued growth and investment within the global non-opioid pain treatment market.

Restraints in the Global Non-Opioid Pain Treatment Market

The Global Non-Opioid Pain Treatment market faces significant challenges due to varying regulatory frameworks and intricate approval processes, which create uncertainty for developers of non-opioid therapies. These factors can lead to delays in product launches across different markets and increase the time and resources necessary for navigating approvals. This complexity can discourage smaller firms from exploring innovative solutions and complicate strategies for global commercialization. Furthermore, differences in clinical trial requirements and post-marketing surveillance expectations may result in fragmented evidence generation, inconsistent adoption by healthcare providers and payers, ultimately restricting investment, hindering product availability, and slowing market growth.

Market Trends of the Global Non-Opioid Pain Treatment Market

The Global Non-Opioid Pain Treatment market is experiencing a significant shift towards precision and personalized therapies, driven by a focus on patient stratification and biomarker-driven approaches. Stakeholders are increasingly investing in personalized formulations, targeted delivery mechanisms, and individualized care pathways, aiming to enhance the efficacy of pain management interventions and improve patient adherence. Collaborations with specialty clinics, diagnostic providers, and pharmaceutical innovators are becoming crucial for developing differentiated value propositions and achieving premium market positioning. Additionally, new market entrants are prioritizing niche segments and patient-centered services that foster long-term engagement and therapeutic relationships, ensuring commercial scalability and sustainable growth.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index 2025
• PESTEL Analysis
• Regulatory Landscape

Global Non-opioid Pain Treatment Market Size by Drug Class & CAGR (2026-2033)

• Market Overview
• NSAIDs
• COX-2 Inhibitors
• Anticonvulsants (Gabapentinoids)
• SNRIs
• Nerve Blocks

Global Non-opioid Pain Treatment Market Size by Pain Type & CAGR (2026-2033)

• Market Overview
• Neuropathic Pain
• Musculoskeletal Pain
• Post-Surgical Pain
• Chronic Pain

Global Non-opioid Pain Treatment Market Size by Route & CAGR (2026-2033)

• Market Overview
• Oral
• Injectable
• Topical

Global Non-opioid Pain Treatment Market Size by End-User & CAGR (2026-2033)

• Market Overview
• Hospitals
• Pain Clinics
• Retail Pharmacies

Global Non-opioid Pain Treatment Market Size & CAGR (2026-2033)

• North America (Drug Class, Pain Type, Route, End-User)
  • US
  • Canada
• Europe (Drug Class, Pain Type, Route, End-User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Drug Class, Pain Type, Route, End-User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Drug Class, Pain Type, Route, End-User)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Drug Class, Pain Type, Route, End-User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Pfizer Inc. (Lyrica)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly (Cymbalta)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie (Cerevel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Averitas Pharma
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Tonix Pharmaceuticals
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Vertex Pharmaceuticals
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Trevena Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Centrexion Therapeutics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Heron Therapeutics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pacira BioSciences
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Adynxx Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Epigenomics AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Grunenthal GmbH
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Assertio Therapeutics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Zyla Life Sciences
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sumitomo Pharma
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Samuels-Pennington
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eliem Therapeutics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Aevi Technologies
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations